STAT

Opinion: Falsehoods and facts about drugs and the people who use them

The issue of drug use is not fundamentally complicated: People will use psychoactive substances, and the first step to more effectively addressing them is to decriminalize their use and possession…
A woman drinks yage in Colombia. Drugs are generally accepted when they are consumed in a traditional manner that a particular culture understands.

A new survey of Americans shows that many regard addiction as a behavioral failing, and most would not welcome those suffering from addiction into their neighborhoods, workplaces, or families. Such attitudes toward addiction, which mirror those in many other countries, perpetuate the abundant false narratives about drugs the world over.

Misrepresentations about drugs fuel stigma and discrimination towards the people who use them. I see this all the time in my work as a member of the Global Commission on Drug Policy. This hinders effective reform and undermines human dignity and the rule of law.

We must find ways to counter prejudice against drug use with facts and break this vicious cycle: drugs are evil and should be illegal → individuals who use them are immoral because drug consumption and possession

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related